Dalton Pharma Services has entered into a contract service agreement with the United States Army Medical Materiel Development Activity (USAMMDA) to support its product development program for the treatment of severe or complicated malaria due to Plasmodium falciparum. Dalton will provide cGMP sterile powder filling, aseptic liquid filling, quality control release testing and ICH stability services.
 
Malaria remains a major infectious disease threat to service members deployed to endemic areas. Despite preventative measures to reduce the risk of malarial infection, service members continue to contract this disease due to operational constraints, lack of compliance, and drug-resistant malarial parasites.
 
“The leadership role taken by USAMMDA in the development of this important therapy for malaria treatment is to be commended, and we are privileged to support this critical program developing safe and effective anti-malarial drugs for emergency treatment protocols,” said Peter Pekos, president and chief executive officer of Dalton.